scholarly journals Allogeneic Hematopoietic Cell Transplant for HIV Patients with Hematologic Malignancies: The BMT CTN-0903/AMC-080 Trial

2019 ◽  
Vol 25 (11) ◽  
pp. 2160-2166 ◽  
Author(s):  
Richard F. Ambinder ◽  
Juan Wu ◽  
Brent Logan ◽  
Christine M. Durand ◽  
Ryan Shields ◽  
...  
Keyword(s):  
Hematologic Malignancies ◽  
Hematopoietic Cell ◽  
Cell Transplant ◽  
Hematopoietic Cell Transplant ◽  
Hiv Patients ◽  
Allogeneic Hematopoietic Cell Transplant

scholarly journals Delivering intensive therapies to older adults with hematologic malignancies: strategies to personalize care

Hematology ◽  
2019 ◽  
Vol 2019 (1) ◽  
pp. 63-70
Author(s):  
Rebecca L. Olin
Keyword(s):  
Older Adults ◽  
Best Practice ◽  
Treatment Plan ◽  
Performance Status ◽  
Intensive Therapy ◽  
Hematologic Malignancies ◽  
Hematopoietic Cell ◽  
Cell Transplant ◽  
Hematopoietic Cell Transplant ◽  
Allogeneic Hematopoietic Cell Transplant

Abstract Intensive therapies are often medically indicated for older adults with hematologic malignancies. These may include induction chemotherapy for acute myeloid leukemia (AML), as well as autologous hematopoietic cell transplant (autoHCT) and allogeneic hematopoietic cell transplant (alloHCT). However, it is not always clear how to best deliver these therapies, in terms of determining treatment eligibility, as well as adjusting or adding supportive measures to the treatment plan to maximize successful outcomes. Beyond performance status and presence of comorbidities, comprehensive geriatric assessment and individual geriatric metrics have increasingly been used to prognosticate in these settings and may offer the best approach to personalizing therapy. In the setting of AML induction, evidence supports the use of measures of physical function as independent predictors of survival. For patients undergoing alloHCT, functional status, as measured by instrumental activities of daily living (IADL) and gait speed, may be an important pretransplant assessment. IADL has also been associated with post-autoHCT morbidity and mortality. Current best practice includes assessment of relevant geriatric metrics prior to intensive therapy, and work is ongoing to develop complementary interventions.

scholarly journals Impact of Letermovir Prophylaxis on Voriconazole Exposure in Allogeneic Hematopoietic Cell Transplant Recipients

2021 ◽  
Vol 27 (3) ◽  
pp. S124
Author(s):  
Issam S. Hamadeh ◽  
Michael R. Grunwald ◽  
Allison Martin ◽  
Jai N. Patel ◽  
Alexandra Wolff ◽  
...  
Keyword(s):  
Hematopoietic Cell ◽  
Cell Transplant ◽  
Transplant Recipients ◽  
Hematopoietic Cell Transplant ◽  
Allogeneic Hematopoietic Cell Transplant
Sign in / Sign up

Export Citation Format

Share Document